In win for generics industry, Viatris wards off $50M payment in tax battle with IRS

Viatris has successfully held its ground in a pitched battle with the IRS over tens of millions of dollars. The case hinges on charges Viatris accrued in patent cases tied to its generic drug approvals early last decade.